0730 GMT - Sanofi's lunsekimig--a potential treatment for asthma--should prove its efficiency, Berenberg analysts write in a note. The French drugmaker's experimental study for moderate-to-severe asthma needs to demonstrate a reduction in asthma exacerbation rate of more of more than 60% and improvements in forced expiratory volume in one second (FEV1) to be competitive, they say. "Lunsekimig could offer less frequent dosing," if every-four-week dosing can be improved upon, and the potential to show efficacy in diverse patient populations with its dual mechanism, they add. Shares are down 0.6% at 78.47 euros.